4Goldsmith SR,Francis GS,Cowley AW Jr,et al. Increased plasma argininevasopressin levels in patients with congestive heart failure [J].J Am Coil Cardiol, 1983,1 : 1385-1390.
5Chin MH,Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure [J].Arch Intern Med, 1996,156:1814-1820.
6Tahara A,Tomura Y,Wada K,et al. Effect of YM087,a potent- nonpeptide vaso-pressin antagonist on vasopresin-induced pro- tein synthesis in neonatal rat car-diomyocyte [J]. Cardiovasc Res, 1998, 38:198-205.
7Nielsen S, Chou CL,Marples D,et al. Vasopressin increases wa-ter permeability of kidney collecting ductby inducing translocation of aquaporin-CD water channels to plasma membrane[J]. Proc Natl Acad Sci USA, 1995,92:1013-1017.
8Udelson JE, McGrew FA,Flores E,et al. Multicenter,randomized, double-blind,placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction [J]. J Am Coll Cardiol, 2007, 49(22) :2151-2159.
9Konstam MA,Gheorghiade M,Burnett JC,et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure:the Everest Outcome Trial[J].JAMA,2007,297(12) : 1319-1331.
10Matsuzaki M,Hori M,Izumi T,et al. Efficacy and safety of tolvap- tan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III,ran- domized,double-blind,placebo-controlled study (QUEST study) [J]. Cardiovasc Drugs Ther, 2011,25 (Suppl 1 ) : 33-45.
